Who
Benjamin L. Oakes
President, CEO
Company insider
Files Form 4 as: President, CEO, Scribe Therapeutics.
In numbers
- Trades disclosed
- 6
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Mar 2026
- Last trade
- 23 Jul 2026
- Last filed
- 27 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —264,784 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —429,599 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —264,784 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —429,599 at $0.00 | filing |
| 13 Mar 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,969 at $0.00 | filing |
| 13 Mar 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,969 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.